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Commentary
The gene encoding interleukin-13: a susceptibility locus for
asthma and related traits
Marsha Wills-Karp
Johns Hopkins University, Baltimore, Maryland, USA
Abstract
Asthma is a complex inflammatory disorder controlled by both genetic and environmental
influences. Multiple genetic analyses have identified the T helper type 2 (Th2) cytokine gene
cluster on chromosome 5q as a susceptibility locus for asthma. Recently, the Th2 cytokine
interleukin-13 has been shown to be a critical mediator of the asthma phenotype in murine
models. In this commentary we discuss several recent studies that have identified
polymorphisms in the gene encoding interleukin-13. The consistent genetic associations of
interleukin-13 with asthma and related traits across diverse ethnic populations in these
studies provides strong support for the candidacy of this cytokine as a susceptibility locus
for asthma and atopy on chromosome 5q31.
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Asthma is a complex inflammatory lung disease controlled
by both environmental and genetic factors. Although the
exact genes controlling susceptibility to asthma have not
been identified, several genome-wide searches have pro-
vided evidence for the linkage of asthma or asthma-related
traits (serum IgE levels, skin test reactivity, bronchial
hyper-responsiveness, blood eosinophils) to loci on multi-
ple autosomal chromosomes [1–6]. Of particular interest
is the 5q31–33 region, which contains the T helper type 2
(Th2) cytokine gene cluster [interleukin (IL)-4, IL-13, IL-5
and IL-9] and has been linked to asthma or related pheno-
types in many studies [2–8]. In addition to the linkage
data, many human and animal studies have implicated
these cytokines, either individually or in concert, in the
pathophysiology of asthma. Of the Th2 cytokines in this
chromosomal region, IL-4 has been extensively studied
because it is known to be important in the differentiation of
T cells into Th2 cytokine-producing cells. A polymorphism
has been identified in the promoter of this gene
(–590C/T) [9] which was initially associated with elevated
serum IgE levels. This polymorphism has been associated
with asthma in some studies [10,11] but not in others
[12–14]. Thus attention has turned to other genes in this
region. Recent studies in animal models that support the
dominance of the gene encoding IL-13, which resembles
IL-4, in the allergic response have spurred an extensive
study of this molecule in susceptibility to asthma [15–17].
The gene encoding IL-13 is located only 25 kilobases
upstream of the gene for IL-4 and in the same orientation,Respiratory Research    Vol 1 No 1 Wills-Karp
leading to the speculation that these genes arose as a
duplication event during evolution. In addition to their
structural similarities they share considerable functional
similarities. They are both known to have a number of
actions relevant to the asthmatic diathesis such as the
regulation of isotype class switching in B cells to IgE syn-
thesis, induction of the expression of major histocompati-
bility complex II and CD23, the induction of adhesion
molecule expression on endothelial cells (vascular cell
adhesion molecule-1), chemokine production (eotaxin), the
activation of mast cells and eosinophils, and the inhibition
of proinflammatory gene expression (IL-1, tumor necrosis
factor and IL-6). This overlap in function is due to the
sharing of a receptor chain in their individual multimeric
receptor complexes (for review see [18]).
The unique IL-4 receptor (IL-4R), which is expressed pri-
marily on cells of hematopoietic origin, is made up of the
common g chain (gc) and the IL-4RA chain. The functional
IL-13 receptor complex is a heterodimer composed of the
IL-4RA chain and the IL-13RA1 chain. There is an addi-
tional IL-13-binding protein referred to as IL-13RA2. This
receptor chain binds IL-13, but not IL-4, with very high
affinity but does not seem to be important in signaling. At
present it is thought to serve as a decoy receptor,
because it has been found in soluble form in vivo. Interest-
ingly, the receptor complex formed by IL-4RA and
IL-13RA1 also serves as a receptor for IL-4 in cells lacking
the gc chain.
Ligation of this complex results in tyrosine phosphorylation
of several signal transduction molecules including insulin
receptor substrate (IRS)-1 and IRS-2, and a member of the
signal transduction and transactivation (STAT) family,
STAT6. STAT6 is phosphorylated by Janus kinases (JAK1
or JAK3), followed by its dimerization and translocation to
the nucleus, where it binds to specific consensus
sequences found within the promoter regions of genes
regulated by IL-4 and IL-13. Sharing of the IL-4RA and
IL-13RA1 receptor complex explains many of the redun-
dancies observed between these two molecules but does
not explain the accumulating evidence that these two
cytokines have unique actions in vivo [15,16,19,20]. One
hypothesis is that the relative distribution of the four recep-
tor chains might dictate the importance of each of these
two cytokines on any given cell type. For example, it is
known that T cells do not express the IL-13RA1 chain, thus
explaining the lack of effect of IL-13 on T cell differentiation.
Furthermore, the presence of the gc chain has been shown
to decrease the binding of IL-13 to the receptor complex
[21]. It will be of interest to determine whether the pres-
ence of the IL-13RA2 chain favors IL-13 binding over IL-4.
Recent murine studies have identified IL-13 as a critical
mediator in the effector phase of the allergic airway
response [15–17]. Specifically, several groups have
shown that blockade of endogenous levels of IL-13 in sen-
sitized mice by the administration of a soluble form of the
IL-13RA2, which binds only IL-13, reverses airway hyper-
responsiveness (AHR) and pulmonary mucous cell hyper-
plasia [15,17], whereas the neutralization of IL-4 does not
[22]. Furthermore, when IL-13 is delivered as a recombi-
nant cytokine to naive mice or is overexpressed in the
lungs of mice they develop a phenotype very similar to that
observed in human asthma (ie AHR, eosinophilic inflam-
mation, mucous cell hyperplasia and subepithelial fibrosis)
[15–17]. In contrast, IL-4 transgenic mice do not develop
AHR or subepithelial fibrosis [23]. Taken together, these
studies suggest that, whereas IL-4 might be essential for
the initial differentiation of CD4 T cells into cells producing
Th2 cytokine, once IL-13 has been produced it is capable
of eliciting the entire allergic phenotype. This contention is
supported by the finding that IL-13 induces allergic
responses in mice lacking functional T cells [16]. Together
these findings demonstrate that IL-13 is a critical mediator
of the effector phase of allergic asthma in experimental
models. The importance of IL-13 in human asthma is sup-
ported by numerous reports of elevated IL-13 levels in the
lungs of asthmatic patients with or without atopy [24,25].
In support of the notion that IL-13 is a central mediator of
asthma, several groups have recently reported associa-
tions of polymorphisms in the IL-13 gene with various fea-
tures of the asthmatic phenotype [13,14,26]. First, Van
der Pouw Kraan et al [26] described a C-to-T nucleotide
exchange at position –1055 in the putative IL-13 pro-
moter. Comparison of the genotype at –1055 in an atopic
asthmatic group (n = 101) with that of a non-atopic
control group (n = 107) revealed a significantly higher fre-
quency (P = 0.002) of homozygous –1055 T carriers in
the atopic asthmatic group in comparison with the non-
atopic controls. In contrast, they found no association of
this polymorphism with total or specific IgE levels or
bronchial hyperresponsiveness in the patient group.
In an effort to determine the functional relevance of this
polymorphism, Van der Pouw Kraan et al examined the
association of the genotype at –1055 in IL-13 with IL-13
protein levels measured in vitro. They demonstrated that
subjects homozygous for –1055 T had significantly differ-
ent levels of IL-13 from those in the –1055 CC or CT
genotypes (P = 0.0016 and P = 0.0002), respectively. As
this region contains a putative binding site for nuclear
factor of activated T cells (NFAT), they examined whether
altered binding of nuclear proteins to this region could
explain the differences in IL-13 promoter activity. They
report that the C to T change at –1055 results in increased
binding of nuclear proteins to this region of the IL-13 pro-
moter. Interestingly, different NFAT proteins have been
shown to regulate IL-4 and IL-13 gene expression differen-
tially. In particular, NFAT-c is thought to be a positive regu-
lator, whereas NFAT1 and NFAT4 might act as repressorsc
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of Th2 cytokine production [27]. It will be of interest in the
future to determine whether in fact the expression of this
variant influences the relative binding of the individual
NFAT proteins. If this variant does indeed lead to the over-
expression of IL-13, it could be an important susceptibility
locus for asthma; however, it would not explain the overex-
pression of the other Th2 cytokines because IL-13 is not
thought to influence Th2 differentiation. Despite the evi-
dence for association of atopic asthma with this polymor-
phism, it is still entirely possible that this variant might be in
linkage disequilibrium with other regions of the IL-13 gene
or surrounding genes on chromosome 5q.
In a screen of more than 200 atopic subjects, Heinzmann
et al [13] identified a single variant (A4464G) in the termi-
nal coding region of the gene for human IL-13 that results
in a predicted amino acid change in residue 110
(Gln110®Arg). To test for a genetic association with clini-
cal asthma and IgE they conducted case control studies in
a British population (150 young adults with asthma and
atopy, and 150 controls) and a Japanese population (100
young adults with asthma and atopy, 100 subjects with
non-atopic asthma, and 100 controls). In the British sub-
jects, Gln110 was significantly associated with asthma
(P = 0.014), whereas Gln110 was associated with both
atopic asthma (P = 0.033) and non-atopic asthma
(P = 0.047) in the Japanese population. Interestingly, they
did not find an association between this genotype and
serum IgE levels in either population (British, P = 0.10;
Japanese, P = 0.508). These results suggest that Gln110
is associated with asthma rather than atopy; however, the
inclusion of an atopic, non-asthmatic group in the analysis
might be needed to clarify this issue. In a follow-up popu-
lation-based survey of genotype frequency in Japanese
schoolchildren aged 12–13 years (n = 290) they found a
significantly higher frequency of Gln110 in asthmatic chil-
dren than in non-asthmatic children. When they examined
the association between serum IL-13 levels and Gln110
they found that children homozygous for Gln110 had sig-
nificantly higher levels of IL-13 than did those homozygous
for Arg110. To begin to understand the biological activity
of the Gln110 variant of IL-13, they conducted computer-
modeling studies based on the assumed homology
between the IL-4 and IL-13 proteins.
The results of the modeling studies suggest that the
Arg130®Gln variant occurs (resides) in a site crucial for
ligand–receptor interactions. Thus Heinzmann et al
hypothesize that the expression of this variant might
result in a protein with enhanced binding affinity for its
receptor. However, so far they have no direct evidence
for this hypothesis. If their assumption is correct,
enhanced activity of IL-13 at its receptor could theoreti-
cally account for many of the features of the allergic phe-
notype (IgE, AHR, hypersecretion of mucus, eosinophilic
inflammation). It is also possible that this polymorphism
could alter the stability of the IL-13 message or the
metabolism of the IL-13 proteins because it was associ-
ated with higher protein levels in the serum.
In a detailed analysis of the gene encoding IL-13, Graves
et al [14] identified seven polymorphisms in the human
gene for IL-13 in a screen of 30 unselected volunteers.
They report two promoter polymorphisms (–1512 and
–1112), one of which is the same (–1112) as that
described by van der Pouw Kraan et al. In addition, they
found five other variants in the IL-13 gene, one in the third
intron (+1923) and three in the 3¢ untranslated region
(+2525, +2580 and +2749). They also identified the
variant described by Heinzmann et al, which they refer to
as Arg130®Gln. In an initial genotyping experiment of
286 white children enrolled in a longitudinal study of
asthma and allergy in Tucson, Arizona, they found that all
of the polymorphisms in the gene encoding IL-13 were in
tight linkage disequilibrium with Arg130®Gln. In a subse-
quent study they assessed the relationship between total
serum IgE and Arg130®Gln and the two polymorphisms
in the IL-13 promoter (–1112 and –1512) in three sepa-
rate study populations of children (Tucson, P = 0.0023;
Leipzig, P = 0.0081; Munich, P = 0.0069); when all sub-
jects were considered, they found stronger associations in
subjects with a negative skin test.
These findings were in contrast with the study by Heinz-
mann et al, in which association of Gln110®Arg was
found with total serum IgE levels in either of the popula-
tions studied. The reason for the discrepancy between
these studies is not entirely clear, but Heinzmann et al did
not examine skin test reactivity as a variable in their analy-
sis. These results also differ from those of the Dutch group
in that they reported no association of the –1055T poly-
morphism with IgE levels, although their patient population
was selected as an atopic asthmatic group. Furthermore,
Graves et al [14] studied children, whereas the other two
studies were conducted with adults. Because IgE levels
change with age, this might have weakened the ability to
detect associations with IgE levels. The fact that Graves et
al found significant linkage disequilibrium between the
independent polymorphisms in the gene encoding IL-13,
including those examined in the studies by both van der
Pouw Kraan et al and Heinzmann et al, suggests that it will
be problematic to discern which, if any, of the polymor-
phisms described so far contribute to asthma and related
traits. Interestingly, one consistent finding in the above
studies was the lack of association of asthma [13] or total
serum IgE [14] with the previously identified IL-4 polymor-
phism (–590C/T). Furthermore, both studies reported that
there was no linkage disequilibrium between the –589
polymorphism in IL-4 and polymorphisms in the gene for
IL-13 [13,14]. A possible explanation for the previous
reports of associations of the IL-4 promoter polymor-
phisms with IgE is that IL-4 –589 is simply a marker for thepolymorphisms in the gene encoding IL-13 or another
enhancer element.
Polymorphisms in the genes for both IL-4RA and IL-
13RA1 have been identified [13,28–31]. In fact, the gene
encoding IL-4RA is located on chromosome 16p12, a
region that has been linked to atopy and asthma in several
populations [29,30]. It was originally reported that a poly-
morphism at position Q576R of the gene for IL-4RA
resulted in enhanced activity of the receptor [28];
however, more recent studies suggest that the altered
receptor activity in cells from asthmatics might be due to
either a different polymorphism or a combination of poly-
morphisms within the gene [30–32]. Defects in the gene
encoding IL-4RA that result in an enhanced capacity to
signal could have a major effect on the immune response
as this receptor is necessary for the signaling of both IL-4
and IL-13. Specifically, enhanced activity of this receptor
could mediate both the IL-4-dependent differentiation of
Th2 cells and the IL-13-dependent processes mediating
the effector phase of the response.
In contrast with IL-4RA, little is known about the role of IL-
13RA1, on chromosome Xq13, in susceptibility to atopy
and asthma. Heinzmann et al [13] have identified three
single-nucleotide polymorphisms in the IL-13RA1. An
analysis of the most common single-nucleotide polymor-
phism, A1398G, showed a marginal association with high
IgE levels (P = 0.021) but not with asthma in the British
population described above. In contrast, no association
was seen with either high IgE levels or asthma in the
Japanese population. Because males are hemizygous at
IL-13RA1, the authors calculated adjusted odds ratios by
sex in the British population. The odds ratio for males was
3.39 (P = 0.015) and 1.10 in females (P = 0.680) for
atopy. Of particular interest is the demonstration that both
the IL-13RA1 chains are expressed on airway epithelial
cells and bronchial smooth muscle cells, suggesting that
these cytokines might have direct actions within the
airways [13]. A determination of the importance of this
variant in asthma pathogenesis awaits additional studies.
The IL-13RA2 chain is also located on the X chromosome;
however, to my knowledge no polymorphisms in this gene
have been identified. One might envision that polymor-
phisms in both the gene encoding IL-13 itself and its two
receptor chains (IL-4RA, IL-13RA1) could affect the sever-
ity of the disease.
In summary, the consistent genetic associations of IL-13
with asthma and related traits across diverse ethnic popu-
lations provides strong support for the candidacy of IL-13
as a major locus for asthma and atopy on chromosome
5q31. Importantly, these associations seem to be indepen-
dent of polymorphisms in the neighboring similar gene, that
encoding IL-4. However, owing to the significant level of
linkage disequilibrium between the polymorphic sites in this
gene, the contribution of surrounding genes on chromo-
some 5q (CD14 [33] or CNS-1[34]), or other as yet
unidentified polymorphisms within the gene for IL-13,
cannot be ruled out. Because asthma is a complex poly-
genic disease, it still remains to be determined whether
expression of the various IL-13 variants alone contributes
significantly to susceptibility to asthma or whether interac-
tions with other genes (those encoding IL-4RA or
IL-13RA1) are required to alter function significantly. Taken
together with the accumulating biological evidence of the
importance of IL-13 in the pathogenesis of asthma, these
results support the contention that IL-13 might be involved
in promoting bronchial asthma in humans. The identification
of variants of IL-13 signaling in the development of asthma
and atopy in humans provides a focus for the development
of novel diagnostic and therapeutic strategies for asthma. It
is certain that these intriguing findings will fuel continued
studies into the specific pathways controlling susceptibility
to asthma in the foreseeable future.
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